Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Talabostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Talabostat is under development for the treatment of metastatic castration resistant small cell neuroendocrine prostate cancer (NEPC), metastatic melanoma, metastatic pancreatic ductal adenocarcinoma, acute myelogenous leukemia (AML) and advanced solid cancers. It is administered orally. It targets dipeptidyl peptidase 8 and 9.
It was also under development for the treatment of non-small cell lung cancer, metastatic adenocarcinoma of the pancreas, metastatic melanoma, chronic lymphocytic leukemia and relapsed or refractory solid tumors including brain tumors.
BioXcel Therapeutics overview
BioXcel Therapeutics is a commercial-stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. Its pipeline product portfolio comprises BXCL501, an adrenergic agent with a sublingual route of administration is used for treating neuropsychiatric and neurodegenerative diseases; BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers; and BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders. The company’s drug re-innovation approach leverages existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to develop new therapeutic candidates. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.
For a complete picture of Talabostat’s drug-specific PTSR and LoA scores, buy the report here.